Portage Biotech Inc Ord (PRTG)

$6.10 +0.40 (7.07%)
Market Cap 6.25M
Revenue (ttm) 0.00
Net Income (ttm) -6.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,030
Avg Vol 106,824
Day's Range N/A - N/A
Shares Out 1.05M
Stochastic %K 23%
Beta 0.23
Analysts Strong Buy
Price Target $140.00

Company Profile

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. Th...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 221 7378
Address:
Clarence Thomas Building, P.O. Box 4649 Road Town, Tortola, British Virgin Islands
Stopcapping
Stopcapping Jul. 25 at 2:47 PM
$PRTG There just holding this here.They own the float so they do whatever they want.If they come out with news this will run hard.
0 · Reply
HectorNumba9
HectorNumba9 Jul. 24 at 10:33 AM
$PRTG the news of phase 3 completed is worth $15 alone so no rush. Imagine the results Just a bunch of traders penny flipping
0 · Reply
PaulLaurent
PaulLaurent Jul. 23 at 7:33 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $CYN $PRTG $SLRX $ADTX $ALBT
1 · Reply
PaulLaurent
PaulLaurent Jul. 17 at 6:47 PM
🧨📈 Potential Squeeze Stocks 📈🧨 $SLRX $LIXT $PRTG $ZENA $XXII
1 · Reply
Stopcapping
Stopcapping Jul. 16 at 11:08 PM
$PRTG Squeeze please!!!!🙏🏼
0 · Reply
Gblue6405
Gblue6405 Jul. 16 at 4:24 PM
$PRTG
0 · Reply
PaulLaurent
PaulLaurent Jul. 15 at 6:45 PM
🧨📈 Potential Squeeze Stocks 📈🧨 $SLRX $BCTX $CTOR $PRTG $SYTA
0 · Reply
PaulLaurent
PaulLaurent Jul. 11 at 1:04 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $BBLG $CYN $GVH $PRTG $ICU
0 · Reply
Stopcapping
Stopcapping Jul. 8 at 10:33 PM
$PRTG Tick tock
0 · Reply
Stopcapping
Stopcapping Jun. 27 at 4:14 PM
$PRTG Just like clockwork this will run 🏃‍♀️!Payday right around corner!!I’ll wait again.They own the float.Ever wonder why it can go 15% on low volume.
0 · Reply
Latest News on PRTG
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Jul 25, 2025, 4:15 PM EDT - 5 days ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Jun 25, 2025, 7:00 AM EDT - 5 weeks ago

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Portage Biotech and Compedica Stock-for-Stock Exchange

Jun 9, 2025, 6:00 AM EDT - 7 weeks ago

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech Stock Surges As It Prepares For Human Trial

Apr 28, 2025, 10:37 AM EDT - 3 months ago

Portage Biotech Stock Surges As It Prepares For Human Trial

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Apr 28, 2025, 6:00 AM EDT - 3 months ago

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Why Is Portage Biotech Stock Skyrocketing Friday?

Mar 28, 2025, 1:13 PM EDT - 4 months ago

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Mar 27, 2025, 6:02 PM EDT - 4 months ago

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Mar 12, 2025, 8:00 AM EDT - 5 months ago

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Feb 12, 2025, 4:15 PM EST - 6 months ago

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Announces Completion of $2.15 Million Private Financing

Jan 30, 2025, 4:30 PM EST - 6 months ago

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Jan 6, 2025, 5:00 AM EST - 7 months ago

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Dec 12, 2024, 4:15 PM EST - 8 months ago

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Nov 26, 2024, 4:05 PM EST - 8 months ago

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Apr 12, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Mar 26, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Feb 28, 2024, 5:10 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Portage Biotech Reports Business and Strategic Update

Jan 4, 2024, 8:00 AM EST - 1 year ago

Portage Biotech Reports Business and Strategic Update

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Nov 28, 2023, 4:01 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 6, 2023, 8:01 AM EST - 1 year ago

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Portage Biotech Announces $6.0 Million Registered Direct Offering

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Portage Biotech Announces $6.0 Million Registered Direct Offering

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Mar 1, 2023, 8:00 AM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Feb 27, 2023, 4:05 PM EST - 2 years ago

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 15, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Nov 29, 2022, 4:43 PM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 9:00 AM EST - 2 years ago

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Nov 8, 2022, 8:00 AM EST - 2 years ago

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Portage Biotech Provides Research and Development Update

Sep 14, 2022, 8:39 AM EDT - 3 years ago

Portage Biotech Provides Research and Development Update

Portage Biotech to Present at Upcoming Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech to Present at Upcoming Investor Conferences

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Aug 29, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Portage Biotech Announces Leadership Updates

Aug 18, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Leadership Updates

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 9:10 AM EDT - 3 years ago

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Jul 20, 2022, 4:07 PM EDT - 3 years ago

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Jul 20, 2022, 9:00 AM EDT - 3 years ago

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Jul 6, 2022, 4:05 PM EDT - 3 years ago

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Apr 13, 2022, 10:00 AM EDT - 3 years ago

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Mar 9, 2022, 9:00 AM EST - 3 years ago

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Feb 24, 2022, 5:43 PM EST - 3 years ago

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Stopcapping
Stopcapping Jul. 25 at 2:47 PM
$PRTG There just holding this here.They own the float so they do whatever they want.If they come out with news this will run hard.
0 · Reply
HectorNumba9
HectorNumba9 Jul. 24 at 10:33 AM
$PRTG the news of phase 3 completed is worth $15 alone so no rush. Imagine the results Just a bunch of traders penny flipping
0 · Reply
PaulLaurent
PaulLaurent Jul. 23 at 7:33 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $CYN $PRTG $SLRX $ADTX $ALBT
1 · Reply
PaulLaurent
PaulLaurent Jul. 17 at 6:47 PM
🧨📈 Potential Squeeze Stocks 📈🧨 $SLRX $LIXT $PRTG $ZENA $XXII
1 · Reply
Stopcapping
Stopcapping Jul. 16 at 11:08 PM
$PRTG Squeeze please!!!!🙏🏼
0 · Reply
Gblue6405
Gblue6405 Jul. 16 at 4:24 PM
$PRTG
0 · Reply
PaulLaurent
PaulLaurent Jul. 15 at 6:45 PM
🧨📈 Potential Squeeze Stocks 📈🧨 $SLRX $BCTX $CTOR $PRTG $SYTA
0 · Reply
PaulLaurent
PaulLaurent Jul. 11 at 1:04 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $BBLG $CYN $GVH $PRTG $ICU
0 · Reply
Stopcapping
Stopcapping Jul. 8 at 10:33 PM
$PRTG Tick tock
0 · Reply
Stopcapping
Stopcapping Jun. 27 at 4:14 PM
$PRTG Just like clockwork this will run 🏃‍♀️!Payday right around corner!!I’ll wait again.They own the float.Ever wonder why it can go 15% on low volume.
0 · Reply
Stopcapping
Stopcapping Jun. 26 at 3:49 PM
$PRTG Stop playing games let it jump!!
0 · Reply
MSC2
MSC2 Jun. 26 at 10:05 AM
$PRTG less than 1
0 · Reply
MSC2
MSC2 Jun. 26 at 10:05 AM
$PRTG should have just delisted this pos
0 · Reply
DancingQueen69
DancingQueen69 Jun. 25 at 8:18 PM
$PRTG I have super heavy bags at 6$
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 25 at 7:53 PM
$SAFX -7%[26%] $NXTT -3%[9%] $XFOR -3%[-10%] $PRTG 3%[19%] $TNGX -3%[-9%] most notable movement into the final minutes of trading.
0 · Reply
PaulLaurent
PaulLaurent Jun. 25 at 7:16 PM
Stocks you should watch $ICU $ADTX $XBIO $IVF $PRTG
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 5:13 PM
$PRTG solid push now…🍾🚨🚀
0 · Reply
mark88arg
mark88arg Jun. 25 at 4:46 PM
$PRTG price prediction end of day ?? tomorrow guys ??
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 4:37 PM
$PRTG not a bad place for a swing idea ..💡--💡..
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 25 at 4:30 PM
$CREV $PRTG $PSTV $QS stocks to watch at 2pm EST for afternoon breakout.
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 4:06 PM
$PRTG she is ready to run..👀🚨👀🚨👀
0 · Reply
Stopcapping
Stopcapping Jun. 25 at 3:56 PM
$PRTG Run this to 30 very possible.23 minimum.
1 · Reply